1. Home
  2. SW vs INSM Comparison

SW vs INSM Comparison

Compare SW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smurfit WestRock plc Ordinary Shares

SW

Smurfit WestRock plc Ordinary Shares

HOLD

Current Price

$43.32

Market Cap

20.6B

Sector

N/A

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$97.85

Market Cap

23.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SW
INSM
Founded
1934
1988
Country
Ireland
United States
Employees
97000
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6B
23.0B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
SW
INSM
Price
$43.32
$97.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
24
Target Price
$53.58
$201.17
AVG Volume (30 Days)
4.5M
3.4M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
4.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.43
$182.31
Revenue Next Year
$3.13
$65.19
P/E Ratio
$38.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.73
$90.39
52 Week High
$52.65
$212.75

Technical Indicators

Market Signals
Indicator
SW
INSM
Relative Strength Index (RSI) 59.88 38.93
Support Level $40.38 N/A
Resistance Level $44.61 $166.81
Average True Range (ATR) 1.74 4.96
MACD 0.27 0.39
Stochastic Oscillator 95.60 40.70

Price Performance

Historical Comparison
SW
INSM

About SW Smurfit WestRock plc Ordinary Shares

Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: